<--- Back to Details
First PageDocument Content
Immunosuppressants / Midwifery / Lactones / Morpholines / Mycophenolic acid / Phenols / IUD with copper / Pregnancy / Combined oral contraceptive pill / Birth control / Diclofenac
Date: 2016-08-03 04:15:11
Immunosuppressants
Midwifery
Lactones
Morpholines
Mycophenolic acid
Phenols
IUD with copper
Pregnancy
Combined oral contraceptive pill
Birth control
Diclofenac

Pharmaceuticals and Medical Devices Safety Information No. 335 August 2016

Add to Reading List

Source URL: www.pmda.go.jp

Download Document from Source Website

File Size: 400,34 KB

Share Document on Facebook

Similar Documents

Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Multiple sclerosis / Medicine / Immunology / Clinical medicine / Autoimmune diseases / Neurological disorders / Neurology / Management of multiple sclerosis / Glatiramer acetate / Immunosuppressants / McDonald criteria / Diagnostic criteria for MS

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / RTT / Biotechnology / Autoimmune diseases / Arthritis / Certolizumab pegol / TNF inhibitor / UCB / Anakinra

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

DocID: 1rakB - View Document

Medicine / Immunology / Clinical medicine / Health care / Immunosuppressants / Biotechnology / Monoclonal antibodies / Immune system / Immunogenicity / Autoimmunity / Infliximab / Arthritis

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document